Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1983 1
1984 1
1985 3
1986 2
1987 1
1988 4
1989 3
1990 2
1991 1
1992 3
1994 1
1995 2
1996 5
1997 4
1998 3
1999 6
2000 8
2001 12
2002 8
2003 5
2004 14
2005 11
2006 16
2007 7
2008 7
2009 7
2010 12
2011 15
2012 12
2013 12
2014 11
2015 8
2016 17
2017 18
2018 18
2019 7
2020 7
2021 8
2022 4
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

266 results

Results by year

Filters applied: . Clear all
Page 1
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.
Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D. Travis WD, et al. Among authors: huber rm. J Thorac Oncol. 2011 Feb;6(2):244-85. doi: 10.1097/JTO.0b013e318206a221. J Thorac Oncol. 2011. PMID: 21252716 Free PMC article. Review.
Gatzemeier U, Griesinger F, Huber RM, Thomas M. Gatzemeier U, et al. Among authors: huber rm. Onkologie. 2008;31 Suppl 3:V. doi: 10.1159/000128573. Onkologie. 2008. PMID: 18545001 Free article. German. No abstract available.
[Lung cancer].
Huber RM, Tufman A. Huber RM, et al. Dtsch Med Wochenschr. 2014 Mar;139(11):545-52; quiz 553-6. doi: 10.1055/s-0033-1349593. Epub 2014 Mar 4. Dtsch Med Wochenschr. 2014. PMID: 24595713 Review. German. No abstract available.
[Quality assurance].
Flentje M, Hoffmann H, Huber RM. Flentje M, et al. Among authors: huber rm. Onkologie. 2012;35 Suppl 3:14-6. doi: 10.1159/000338990. Epub 2012 May 15. Onkologie. 2012. PMID: 22678020 Free article. German. No abstract available.
[Lung cancer].
Huber RM. Huber RM. Internist (Berl). 2006 Jun;47(6):611-20; quiz 621. doi: 10.1007/s00108-006-1581-3. Internist (Berl). 2006. PMID: 16767476 Review. German.
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy).
Brunelli A, Charloux A, Bolliger CT, Rocco G, Sculier JP, Varela G, Licker M, Ferguson MK, Faivre-Finn C, Huber RM, Clini EM, Win T, De Ruysscher D, Goldman L; European Respiratory Society and European Society of Thoracic Surgeons joint task force on fitness for radical therapy. Brunelli A, et al. Among authors: huber rm. Eur Respir J. 2009 Jul;34(1):17-41. doi: 10.1183/09031936.00184308. Eur Respir J. 2009. PMID: 19567600 Free article.
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, Huber RM, West HL, Groen HJM, Hochmair MJ, Leighl NB, Gettinger SN, Langer CJ, Paz-Ares Rodríguez LG, Smit EF, Kim ES, Reichmann W, Haluska FG, Kerstein D, Camidge DR. Kim DW, et al. Among authors: huber rm. J Clin Oncol. 2017 Aug 1;35(22):2490-2498. doi: 10.1200/JCO.2016.71.5904. Epub 2017 May 5. J Clin Oncol. 2017. PMID: 28475456 Free article. Clinical Trial.
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS. Rizvi NA, et al. Among authors: huber rm. Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9. Epub 2015 Feb 20. Lancet Oncol. 2015. PMID: 25704439 Free PMC article. Clinical Trial.
Black and Blue.
Kauffmann-Guerrero D, Kahnert K, Pratschke S, Angstwurm M, Tufman A, Huber RM. Kauffmann-Guerrero D, et al. Among authors: huber rm. Respiration. 2017;94(5):465-466. doi: 10.1159/000479703. Epub 2017 Sep 7. Respiration. 2017. PMID: 28877530 Free article. No abstract available.
[Intensive insulin therapy].
Landgraf R, Huber RM, Bachmann A, Lohr R. Landgraf R, et al. Among authors: huber rm. Dtsch Med Wochenschr. 2008 Apr;133(17):901-12. doi: 10.1055/s-2008-1075668. Dtsch Med Wochenschr. 2008. PMID: 18415916 Review. German. No abstract available.
266 results